6-[[[4-(环丙基甲基)-1-哌嗪基]甲基]-2-(5-氟-1H-吲哚-4-基)-4-(4-吗啉基)-噻吩并[3,2-d]嘧啶 | 955977-50-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩并嘧啶酮衍生物
• 中文名称: 6-[[[4-(环丙基甲基)-1-哌嗪基]甲基]-2-(5-氟-1H-吲哚-4-基)-4-(4-吗啉基)-噻吩并[3,2-d]嘧啶
• 中文别名: 6-[[4-(环丙基甲基)-1-哌嗪基]甲基]-2-(5-氟-1H-吲哚-4-基)-4-(4-吗啉基)噻吩并[3,2-D]嘧啶；PI-3065抑制剂；4-(6-((4-(环丙基甲基)哌嗪-1-基)甲基)-2-(5-氟-1H-吲哚-4-基)噻吩并[3,2-D]嘧啶-4-基)吗啉；PI-3065
• 英文名称: PI-3065
• 英文别名: 4-(6-((4-(cyclopropylmethyl)piperazin-1-yl)methyl)-2-(5-fluoro-1H-indol-4-yl)thieno[3,2-d]pyrimidin-4-yl)morpholine；4-[6-[[4-(cyclopropylmethyl)piperazin-1-yl]methyl]-2-(5-fluoro-1H-indol-4-yl)thieno[3,2-d]pyrimidin-4-yl]morpholine
• CAS: 955977-50-1
• 化学式: C₂₇H₃₁FN₆OS
• 分子量: 506.647
• InChiKey: YDNOHCOYQVZOMC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  36
• 可旋转键数：
  6
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.48
• 拓扑面积：
  88.8
• 氢给体数：
  1
• 氢受体数：
  8

安全信息

• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

文献信息

• PYRIMIDINE DERIVATIVES AS PI3K INHIBITORS
  申请人：Baker Stewart James

  公开号：US20100016306A1

  公开（公告）日：2010-01-21

  Thienopyrimidines of formula (Ia) or (Ib): wherein R 1 -R 3 have any of the values described herein, and the pharmaceutically acceptable salt thereof have activity as inhibitors of PI3K and may thus be used to treat diseases and disorders arising from abnormal cell growth, function or behaviour associated with PI3 kinase, in particular the p110 delta subtype, such as immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine disorders and neurological disorders. Processes for synthesizing the compounds are also described.

  式(Ia)或(Ib)的噻唑并[3,2-d]嘧啶类化合物：其中R1-R3具有以下任何一种所述的值，以及其药学上可接受的盐具有PI3K抑制剂活性，因此可用于治疗由于PI3激酶异常细胞生长、功能或行为引起的疾病和障碍，特别是p110 delta亚型，例如免疫障碍、心血管疾病、病毒感染、炎症、代谢/内分泌障碍和神经障碍。还描述了合成该化合物的方法。
• PHARMACEUTICAL COMPOUNDS
  申请人：Baker Stewart James

  公开号：US20120283257A1

  公开（公告）日：2012-11-08

  Thienopyrimidines of formula (Ia) or (Ib): wherein R 1 -R 3 have any of the values described herein, and the pharmaceutically acceptable salt thereof have activity as inhibitors of PI3K and may thus be used to treat diseases and disorders arising from abnormal cell growth, function or behaviour associated with PI3 kinase, in particular the p110 delta subtype, such as immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine disorders and neurological disorders. Processes for synthesizing the compounds are also described.

  公式（Ia）或（Ib）的噻唑嘧啶类化合物：其中R1-R3具有此处所述的任何值，其药学上可接受的盐具有PI3K抑制剂活性，因此可用于治疗由与PI3激酶相关的异常细胞生长、功能或行为引起的疾病和障碍，尤其是p110 delta亚型，如免疫障碍、心血管疾病、病毒感染、炎症、代谢/内分泌障碍和神经障碍。还描述了合成这些化合物的过程。
• PHOSPHATIDYLINOSITOL-3-KINASE P110 DELTA-TARGETED DRUGS IN THE TREATMENT OF CNS DISORDERS
  申请人：The U.S.A. As Represented By The Secretary, Department Of Health And Human Services

  公开号：EP2365810A2

  公开（公告）日：2011-09-21
• Optimized Method for Treating and Curing Arthritis, Diabetes, Multiple Sclerosis and Other Autoimmune Disease
  申请人：Postrel Richard

  公开号：US20190070166A1

  公开（公告）日：2019-03-07

  The present invention teaches a method, system and process for curing, treating and diagnosing arthritis, diabetes and other related autoimmune diseases. By intercepting and mitigating the disease process at the point of origination prevents the disease from developing and stops the lineage of cells causing disease symptoms. This fundamental system addresses cellular events where the immune reaction is emerging thereby preventing advance of the cascade that feeds the disease. Modulating activity of the errant protein at this initiating point in the immune response blocks the autoimmune cascade and prevents formation of secondary and tertiary effects that will characterize the disease. As the cascade progresses, the number of participating enzymes and pathways compounds so that each progression step further from the initiation point requires increasingly complex therapies. Thus, by treating the primary cause, secondary and tertiary symptoms do not appear. This avoids the side effects observed in multi-faceted approaches presently used to manage the disease symptoms rather than disease causation.
• Inhibitors of HSP90, PI3-Kinase, Proteasome, HDAC, and P97 Pathways for Selective Removal of Senescent Cells in the Treatment of Age Related Conditions
  申请人：Unity Biotechnology, Inc.

  公开号：US20200360386A1

  公开（公告）日：2020-11-19

  Senescent cell medicine encompasses the paradigm that many conditions that are associated with aging or tissue damage are caused or mediated by senescent cells. This disclosure shows that HSP90, pI3-kinase, proteasome, HDAC, and p97 pathways are all active in senescent cells, and can be used as an effective means for removing senescent cells from a target tissue. Exemplary inhibitors of each of these pathways are provided. Also provided is a new genus of p97 inhibitor molecules. The structure includes a core 4 amino pyrimidine ring system, substituted at the 2 position with a nitrogen atom of an amino substituent or a N heterocycle. The 4 amino substituent of the core ring system is optionally linked to a substituted phenyl group. Any of the inhibitors referred to in this disclosure can be screened for senolytic activity and developed for the treatment of conditions such as osteoarthritis, ophthalmic disease, pulmonary disease, and atherosclerosis.